Skip to main content

Table 3 Univariate analyses of various clinical parameters in prostate cancer patients

From: Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer

ParametersProgression-Free SurvivalCancer-Specific SurvivalOverall Survival
HR (95% CI)P-valueHR (95% CI) P-valueHR (95% CI)P-value
Age (years)0.969 (0.948–0.990)0.0040.971 (0.944–1.000)0.0500.988 (0.962–1.015)0.396
PSA (μg/L)1.000 (1.000–1.001)0.2281.000 (1.000–1.001)0.2731.000 (0.999–1.001)0.611
Gleason Score < 0.001 < 0.001 < 0.001
  ≤ 71 1 1 
  > 72.907 (2.006–4.211) 6.425 (3.265–12.643) 4.740 (2.733–8.220)
Metastasis < 0.001 < 0.001 < 0.001
 No1 1 1 
 Yes3.528 (2.443–5.096) 7.920 (4.024–15.589) 4.122 (2.496–6.809) 
Risk Stratification 0.023 0.069 0.095
 Lowintermediate1 1 1 
 High2.428 (1.133–5.205)24.120 (0.779–746.903) 2.357 (0.861–6.447)
PNI 0.004 0.001 < 0.001
  < 50.21 1 1
  ≥ 50.20.590 (0.414–0.841) 0.391 (0.226–0.676) 0.407 (0.250–0.662) 
  1. Abbreviations: HR Hazard ratio; CI Confidence interval; PSA Prostate-specific antigen; PNI Prognostic nutritional index